THERAVANCE BIOPHARMA INC (TBPH:NASDAQ)
$16.93 -0.04 (-0.2357%)
Analysed THERAVANCE BIOPHARMA INC (TBPH:NASDAQ) News Sources
THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT
29-06-2026
yahoo.com
Zymeworks to Acquire Theravance Biopharma, Inc.
29-06-2026
yahoo.com
Zymeworks to Acquire Theravance Biopharma in $929 Million Deal
29-06-2026
yahoo.com
Zymeworks to Buy Theravance for Lung Disease Drug. Both Stocks Are Sliding.
29-06-2026
yahoo.com
Zymeworks To Buy Theravance Biopharma In $929M Deal – A Look At What This Deal Means For TBPH Shareholders
29-06-2026
stocktwits.com
Sector Update: Healthcare Stocks Higher Late Afternoon
29-06-2026
yahoo.com
Zymeworks agrees to buy Theravance Biopharma for $929m
30-06-2026
pharmaceutical-technology.com
Theravance Stock Down 3% After Zymeworks Announces Buyout
30-06-2026
yahoo.com
Zymeworks (ZYME) Stock Looks Fully Valued Despite Its 205% Three Year Run
01-07-2026
yahoo.com
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
16-07-2026
yahoo.com
What is the current price of THERAVANCE BIOPHARMA INC (TBPH:NASDAQ)?
The current price of THERAVANCE BIOPHARMA INC (TBPH:NASDAQ) is $16.93.
THERAVANCE BIOPHARMA INC (TBPH:NASDAQ) absolute price change since previous trading day?
The absolute price change of THERAVANCE BIOPHARMA INC (TBPH:NASDAQ) since the previous trading day is $-0.04.
THERAVANCE BIOPHARMA INC (TBPH:NASDAQ) percentage price change since previous trading day?
The percentage price change of THERAVANCE BIOPHARMA INC (TBPH:NASDAQ) since the previous trading day is -0.2357%.
What is the most recent average sentiment score for THERAVANCE BIOPHARMA INC (TBPH:NASDAQ)?
The most recent average sentiment score for THERAVANCE BIOPHARMA INC (TBPH:NASDAQ) is 73 out of 100.
What is the most recent average sentiment for THERAVANCE BIOPHARMA INC (TBPH:NASDAQ)?
The most recent sentiment for THERAVANCE BIOPHARMA INC (TBPH:NASDAQ) is .
SEC-8K** Filing Available For THERAVANCE BIOPHARMA INC (TBPH:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.